Immunitybio Inc IBRX

US Biotechnology

$7.17 ▼ -3.76% ($-0.28)

🔥 High Short Interest 📅 Earnings This Week

Open $7.45

Prev Close $7.45

Day Range $7.10 – $7.62

52W Range $1.95 – $12.43

Market Cap $7.51B

Beta 0.15

EPS (TTM) $-0.85

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2015-07-28
Shares Out.	1,047,350,000
Website	immunitybio.com/ ↗
Phone	13026587581
Employees	691
Revenue	$44.2M
Gross Profit	$44.0M
Net Income	-$632.8M
Free Cash Flow	-$298.9M
Total Assets	$646.6M
Total Liabilities	$1.52B
Equity	-$869.1M

About Immunitybio Inc

ImmunityBio Inc is a biotechnology company focused on developing and commercializing next-generation immunotherapies designed to activate the patient's immune system and provide durable protection against cancer and infectious diseases. Its approach harnesses both the adaptive and innate immune systems with the Cancer BioShield platform. The platform is built around the proprietary IL-15 superagonist ANKTIVA (nogapendekin alfa inbakicept) and is supported by a portfolio that includes adenovirus-vectored vaccines, NK-cell therapies, and additional immunomodulators. The company operates in the United States and Europe, with the majority of its revenue coming from the United States.

Immunitybio Inc is a publicly traded company under the ticker symbol IBRX on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.